Heidelberg Pharma
Update in progressHPHA.DE (XETRA)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Heidelberg Pharma AG is a Germany‑based biopharma focused on oncology and antibody–amanitin conjugates (ATAC). Key programs include HDP‑101, an anti‑BCMA antibody in Phase I/IIa for relapsed/refractory multiple myeloma; HDP‑102 (preclinical) for non‑Hodgkin lymphoma; HDP‑103 for metastatic castration‑resistant prostate cancer; HDP‑104 for GI tumors; HDP‑201 for colorectal cancer; TAK‑ATAC for oncology. TLX250‑CDx for kidney cancer (Phase III) and TLX250/girentuximab (Phase II). RHB‑107 for COVID‑19 (Phase II). Licensing with Huadong Medicine for Asia. Formerly Wilex, renamed 2017; founded 1997; based in Ladenburg.
Company score
- Sentiment
- -0.49
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.41
- Governance
- -0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.16
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketXETRA (GER)
- LocationGermany
- CEODr. Dongzhou Liu Ph.D.
- Founded1997
- Employees41
- Websiteheidelberg-pharma.com
Identifiers
- ISINDE000A11QVV0